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Key Points
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Abstract Title:
An Exploratory Data Survey of Drug Name Incidence and Prevalence From the FDA's  Adverse Event 
Reporting System, 2004-2012Q2
Purpose: 
To count and monitor the drug names reported in the publicly available version of the Federal Adverse 
Event Reporting System (FAERS) from 2004-2012Q2 in a maximized sensitivity relational model.
Methods: 
Data mining and data modeling was conducted and event based summary statistics with plots were 
created from nine continuous years of FAERS data. 
Results:
This FAERS model contains 344,452 individual drug names and 432,541,994 drug name count 
references which occurred across 4,148,761 human subjects in the 34 quarter study period. FAERS has 
several trending outbreaks of drug name incidence reported for Adverse Events (AE). Plots for the top 
100 scoring drug name references are reported by year and quarter; the top 100 drug names contain 
143,384,240 references or 33% of all drug name references over 34 quarters of continuous FAERS 
data.
Conclusions: 
While FAERS contains many drugs and adverse event reports, its data pertains to very few of them. 
Drug name incidence lends timely and effective surveillance of large populations of Averse Event 
Reports and does not require the cause of the AE, nor its validity to be known to detect a mass 
poisoning. Drug name surveillance and incidence reporting may serve as viable alternative to odds 
ratio’s and other Gaussian based statistical approaches when a maximized sensitivity relational model 
is used. 
Introduction
The Federal Adverse Event Reporting System (FAERS) data set is a massive, publicly available 
pharmacoepidemiology repository for worldwide post marketing drug surveillancei. FAERS is 
populated with provider reported data points describing Adverse Events (AE) experienced by patients 
who consume marketed pharmaceutical drugs in patient care settings. As more and more drugs are 
marketed over time and access to western pharmaceuticals continues to grow it stands to reason that we 
will see more adverse events. How many adverse events is too manyii for a single drug name is a 
question of active debate, with obvious cases like (contaminated) Heparin Sodium Injection (HSI)iii and 
VIOXXiv on one hand and well debated yet indecisive cases like Aspirinv on the other. While these drug 
names are often explored in FAERS in terms of historical trendsvi of individual drug names, odds ratio  
signal dis-proportionality and mortality surveillancevii, the literature fundamentally lacks summary 
statistics for all drug names in FAERS or a drug name to drug names comparison.
Here, a maximum sensitivity model is crafted from FAERS reports from 2004-2012Q2; utilizing the 
FDA’s publicly available database. This data source is largely discarded as a research resource because 
FAERS contains over 300,000 drug names for a highly likely 10,000 substancesviii. This inflation is 
largely due to spelling errors and open input data string fields. Further there is widespread criticism that 
FAERS does not contain meaningful data in the public version and that most impressive data elements 
are reserved for government investigators in the name of patient information protectionsix. These 
concerns are accurate, but must be tempered by efforts to develop surveillance methodologies that can 
resolve these static roadblocks that have shown no sign of moving despite years of publicly available 
surveillance data. 
FAERS uses a three tier index model where drug names are tied to clinical indications and observed 
reactions by the reporting provider. A patient may have several drugs (poly pharmacyx), indications (co-
morbidity) and reactions (adverse or clinical, known or unknown) in any single subject level report. A 
host of secondary variables, including patient outcome is also available. Several common statistical and 
epidemiological methods of mining FAERS may well be inappropriate given the structure, distribution 
and shape of FAERS drug name incidence and prevalence. 
For a direct example, a patient on ten drugs with four indications and two reactions returns six drug 
name counts across each of the ten drugs for the individual subject in this model, inflated by indication 
and reaction. To become a high count relational drug name this must happen to a specific drug 
disproportionately across bodies or time. Although this model sacrifices the clinical sensitivity that 
many providers and toxicologists look to FAERS to provide, it allows epidemiologists to describe in 
explicit detail the incidence and relevance of reported drug name relationships over time. More 
complex FAERS reports suggest more complex management of and therefore spontaneous or unknown 
reactions and severe subject level clinical complications. Population level events outside of bedside 
matters are well suited to maximum sensitivity detection methods like this. 
Knowing the noise from the pharmacokinetics is a major undertaking of data science and 
pharmacology. Signal based reporting was supposed to solve this problemxi, yet signal work is largely 
derived from single drug odds ratiosxii xiiithat assume proportional incidence can be subject to false 
positives and noisexiv. By assuming FAERS reports are false until proven true (as if FAERS reports 
were populated by clinical providers by accidentxv) we obscure and deliberately under power FAERS 
signals with overly complicated mathematical models. Different and multiple approaches to AE 
surveillance may resolve longstanding dissatisfaction with championed single method approaches. 
Methods
Subject numbers (ISR) were left joined to their reported drug names, then clinical indications and 
finally reactions. This set was then striped of its subject level identifiers in Microsoft Access 2008. 
Further, clinical indication and specific reaction were also striped from the model to create a relational 
count data model of drug names by quarter using Google API Big-Query. This model assumes every 
reported drug name in FAERS actually influenced an adverse event and that in a population level 
perspective, higher count values indicate more problematic substances. While FAERS probably 
contains false positives, they most likely did not happen across the available, international and 
historical patient population contained in FAERS. Plots were constructed using Microsoft Excel 2007, 
RED-R (R programming languagexvi) and CIRCOSxvii. Summary statistics were computed in SPSS 19. 
Results
Table One: Model Values
 Over 75% of the 344,452 drug names in FAERS contained less than forty relational counts across 
4,148,761 human subjects and 34 reporting quarters. Despite maximum sensitivity most drug names 
failed to capture a meaningful volume of references over time suggesting non-population level AE but 
individual patient AE. Some drug names returned millions of counts suggesting mass poisonings. 
Table Two: Quarterly (Q) Measures for The Top Ten Scoring Drug Names
HSI is the largest scoring drug name in the model  followed by the widely used and debated Aspirin. 
The distinction between their QSUM is telling as HSI is nearly three times larger than Aspirin. Several 
drugs beat out VIOXX for the third spot on the list and warrant further investigation. The range 
between the QMIN and QMAX may prove adequate to detect departures from the norm if taken with 
median and average taken as baseline values. All values are quarterly except QSUM.  Mass poisoning 
events are detectable when historical subservience is utilized. 
Graph One: Box Plot of Drug Name Reference Counts by Quarter
VIOXX (Graph 1 Box Plot Left) and HEPERIN SODIUM INJECTION (Graph 1 Box Plot Right) are 
clearly legible and served for the top scoring values over several quarters of documented historical 
incidence. This data model can clearly detect departure from the trend with simplistic incidence survey 
work. 
Graph Two: Population Level Ratio Trend Variation in FAERS
Here we see the total population from the study period by quarter divided by the number of drug name 
reference events by quarter and plotted against the percentage of reporting subjects and drug name 
reference events from the study period. We clearly see that while there is no stable rate or neutral state 
in FAERS there are strong departures from the norm, especially coinciding with HSI contamination.  
VIOXX and other poisoning events are not readily legible here, suggesting that some mass poisonings 
are obscured by proportional surveillance. If FAERS is a natural pattern without variation, the affected 
human population and drug name counts should return similar percentages over time. There are several 
departures from the expected 1:2 ratio, where the complexity of the adverse event outpaced the human 
population experiencing it. 
Top 100 Sum Drug Name References Set Plotted by Year and Quarter 2004-2012
This set contains 100 drug names and 33% of FAERS drug name count references over nine continuous 
years.
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Discussion:
There is an order of operations to population level epidemiology: sensitivity, outbreak identification, 
specificity, case definition and then automated surveillance. This maximum sensitivity model may be 
complicated to understand as it has no specificity controls. In the first step specificity or cause is not 
required, rather detection is key. These AE case definitions emerge from drilling down into initial 
sensitivity surveillance. This model can detect signals of AE despite the equal power that relational 
modeling lends to assumed false positives. Further, historical epidemics of AE (VIOXX and HSI) are 
detectable. 
Most importantly this model does not rely on any base measure of a drug over time but rather compares 
a drug to drugs across clinical complexity within and across quarters. VIOXX may be a successful yet 
late intervention; as most surveillance schemes look for increases in reporting for a baseline that was 
never natural. Further, online supplement Graph FAERS 2006 clearly demonstrates the power and 
utility of FAERS by highlighting the near evaporation of VIOXX cases by the second quarter of 2006; 
for which mass legal actionxviii rather than marketing practices may well be responsible. Further utility 
can be seen in countless label changes, black box warnings and direct actions taken by the FDA. 
Increasingly FAERS has fallen under somewhat unwarranted criticism for not detailing epidemics or 
naming drugs as endemic causes of AE fast enough. This model details the kinds of utility that may be 
found in an adverse event reporting system like FAERS and suggest drug names for further 
investigation. Maximum sensitivity seems to coincide with major epidemics of AE including VIOXX 
and HSI, suggesting that other model values may also be valid. High scoring drugs warrant further 
epidemiological investigation, as these signals are equally powered in this maximum sensitivity model 
as VIOXX and HSI. 
Conclusion
FAERS presents challenges and rewards in an endless waltz of suspicion, corroboration and false 
positives in traditional surveillance scheme. Novel approaches as well as model, relational and 
dimensional analysis may supplement formal surveillance programs. While more invention, 
collaboration and expertise are often called upon to supplement surveillance efforts, an old fashioned 
closed set count data model has demonstrated some utility. 
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